MARKET

CLBS

CLBS

Caladrius
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.560
0.000
0.00%
Opening 14:11 06/22 EDT
OPEN
1.620
PREV CLOSE
1.560
HIGH
1.620
LOW
1.541
VOLUME
580.20K
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
1.250
MARKET CAP
92.82M
P/E (TTM)
-6.0938
1D
5D
1M
3M
1Y
5Y
Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease
Benzinga · 3h ago
Caladrius Bio to assess CLBS201 in diabetic kidney disease
Caladrius Biosciences (CLBS) announces that the FDA has authorized its investigational new drug ((IND)) application for the study of CLBS201, a CD34+ cell therapy for the treatment of diabetic kidney
Seekingalpha · 5h ago
BRIEF-Caladrius Biosciences To Assess Its Clbs201 Cd34+ Cell Therapy In Diabetic Kidney Disease
reuters.com · 5h ago
Caladrius Biosciences Says To Assess Its CLBS201 CD34+ Cell Therapy In Diabetic Kidney Disease
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
Benzinga · 6h ago
Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease
Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration...
GlobeNewswire · 6h ago
Caladrius Biosciences to Move Forward With Clinical Program for CLBS201 in Diabetic Kidney Disease
MT Newswires · 8h ago
21 Stocks Moving in Monday's Pre-Market Session
Gainers Raven Industries, Inc. (NASDAQ: RAVN) rose 47.2% to $56.86 in pre-market trading. CNH Industrial N.V
Benzinga · 1d ago
Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit
Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and Ch...
GlobeNewswire · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLBS. Analyze the recent business situations of Caladrius through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLBS stock price target is 8.67 with a high estimate of 10.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 6.75M
% Owned: 11.34%
Shares Outstanding: 59.50M
TypeInstitutionsShares
Increased
11
4.41M
New
6
579.93K
Decreased
4
95.07K
Sold Out
9
554.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.48%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Chairman/Independent Director
Gregory Brown
President/Chief Executive Officer/Director
David Mazzo
Senior Vice President/General Counsel/Secretary
Todd Girolamo
Other
Robert Honigberg
Director
Michael Davidson
Director
Anne Whitaker
Independent Director
Steven Klosk
Independent Director
Steven Myers
Independent Director
Cynthia Schwalm
Independent Director
Peter Traber
No Data
  • All
  • Financials
  • Insiders
More
About CLBS
Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. It also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.

Webull offers kinds of Caladrius Biosciences Inc stock information, including NASDAQ:CLBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLBS stock methods without spending real money on the virtual paper trading platform.